HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

cerivastatin (Kazak)

Subscribe to New Research on cerivastatin

cerivastatin is the ((E)-(+))-isomer; structure given in first source

Also Known As:

Kazak; Certa; Baycol; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, monosodium salt, (S-(R*,S*-(E)))-; 7-(4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyrid-3-yl)-3,5-dihydroxy-6-heptenoate sodium salt; Bay w 6228; Bayer brand of cerivastatin sodium; Knoll brand of cerivastatin sodium; Lipobay; cerivastatin sodium; rivastatin

Networked: 283 relevant articles (15 outcomes, 65 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyridines: 41
    - cerivastatin: 283

Experts

1.	Liu, Fen: 4 articles (01/2015 - 11/2010)
2.	Xie, Xiang: 4 articles (01/2015 - 11/2010)
3.	Psaty, Bruce M: 4 articles (07/2013 - 12/2004)
4.	Jacobson, Terry A: 4 articles (03/2013 - 05/2003)
5.	Liu, Jiyan: 3 articles (01/2015 - 01/2012)
6.	Zhang, Xing: 3 articles (01/2015 - 01/2012)
7.	Zhang, Wanjiang: 3 articles (01/2015 - 01/2012)
8.	Wu, Fang: 3 articles (01/2015 - 01/2012)
9.	Li, Ji-Cheng: 3 articles (01/2015 - 01/2012)
10.	Jiang, Tingting: 3 articles (01/2015 - 01/2012)

Related Diseases

1.	Hypercholesterolemia 08/27/1998 - "In conclusion, these studies indicate that cerivastatin is a safe and effective long-term treatment for patients with primary hypercholesterolemia and also suggest that higher doses should be investigated." 07/24/2001 - "Twenty-seven elderly diabetic patients (aged 69.3+/-3.4 years), with or without mild hypercholesterolemia, were enrolled in this study, which tested cerivastatin treatment (0.15 mg/d) for 3 days. " 08/27/1998 - "Phase IIa clinical studies with cerivastatin--including 2 pilot US and European dose-ranging studies, and 1 US dose-scheduling study--were conducted to establish a dosage regimen and effective therapeutic doses of cerivastatin in the treatment of hypercholesterolemia. " 06/01/2002 - "The efficacy and safety of the new statin, cerivastatin, in the Chinese patients with primary hypercholesterolemia remains to be determined. " 09/01/2001 - "Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia."
2.	Rhabdomyolysis 07/01/2013 - "This study had three components: (a) resequencing the SLCO1B1 gene in 122 patients who developed rhabdomyolysis while on cerivastatin; (b) functional evaluation of the identified SLCO1B1 nonsynonymous variants and haplotypes in in-vitro HEK293/FRT cells stably transfected with pcDNA5/FRT empty vector, SLCO1B1 reference, variants, and haplotypes; and (c) in-vitro screening of 15 drugs commonly used among the rhabdomyolysis cases for inhibition of OATP1B1-mediated uptake of cerivastatin in HEK293/FRT cells stably transfected with reference SLCO1B1. " 04/17/2006 - "For statins other than cerivastatin, the incidence of rhabdomyolysis in 2 cohort studies was 3.4 (1.6 to 6.5) per 100,000 person-years, an estimate supported by data from 20 randomized controlled trials. " 12/01/2004 - "The company continued to conduct safety studies, some of them inadequately designed to assess the risk of rhabdomyolysis, until cerivastatin was removed from the market in August 2001. " 07/01/2013 - "Reduced function of OATP1B1 related to genetic variation and drug-drug interactions likely contributed to cerivastatin-induced rhabdomyolysis. " 07/01/2013 - "We investigated whether patients exhibiting rhabdomyolysis who were taking cerivastatin possess functional genetic variants in SLCO1B1 and whether they were on concomitant medications that inhibit OATP1B1, resulting in accumulation of cerivastatin. "
3.	Muscular Diseases (Myopathy) 11/01/2001 - "After marketing withdrawal of cerivastatin physicians asked several questions regarding the efficacy and safety of statins, the real risk of myopathy, the compared efficacy of all the statins, the reasons why severe adverse events could happen despite several long-term randomized controlled trials, the approval from regulatory agencies. " 01/01/2009 - "Rare instances of myopathy are associated with all statins, but cerivastatin was withdrawn from clinical use due to a greater incidence of myopathy. " 04/17/2006 - "Rates of hospitalization due to AEs in patients on monotherapy with currently available statins were similar, whereas the incidence of hospitalization for muscle disorders increased 6.7-fold with cerivastatin therapy. " 04/17/2006 - "The cerivastatin NDA, along with its supplementary NDA, was the first to demonstrate a clear statin dose-response relation with myopathy and a threshold effect above which myotoxicity increases significantly. " 05/01/2005 - "[Severe muscle disorders associated with statins: analysis of cases notified in France up to the end of February 2002 and data concerning the risk profile of cerivastatin]."
4.	Neoplasms (Cancer) 03/01/2003 - "In this report, a molecular mechanism to explain its anti-cancer action is proposed by combining the study of cerivastatin effect on both gene expression (microarray) and signal transduction pathways. " 06/01/2004 - "Cerivastatin did not affect capillary density in tumors. " 08/01/2001 - "In conclusion, our results suggest that cerivastatin inhibits cell signaling pathways involved in the invasiveness and metastatic properties of highly invasive cancers." 08/27/1998 - "There was no evidence that cerivastatin had any mutagenic effects and, in contrast to other statins, high doses of cerivastatin did not induce tumors in rats. " 06/01/2004 - "Cerivastatin enhanced blood flow recovery in the ischemic hind limb as determined by laser Doppler imaging, whereas tumor growth was significantly retarded. "
5.	Dyslipidemias (Dyslipidemia) 01/01/2014 - "This study investigated the prevalence and distribution of dyslipidemia in adults of Uygur, Kazak, and Han ethnicity in Xinjiang, China. " 01/01/2015 - "We have investigated the relationship between the polymorphisms and haplotypes in the CETP gene, and dyslipidemia among the Xinjiang Kazak and Uyghur populations in China. " 01/01/2014 - "The prevalence rates of dyslipidemia in Uygur, Kazak, and Han adults in Xinjiang are higher than the average levels in China, with significant differences in ethnicity, age, and gender. " 01/01/2014 - "The overall prevalence rates of dyslipidemia in Uygur, Kazak, and Han adults were 42.4, 31.6, and 30.2%, respectively; they were 42.4, 31.8, and 28.2% after age standardization (P < 0.01). " 01/01/2014 - "Among the participants with dyslipidemia, the proportion of those who aware, treat, control of dyslipidemia were 53.67%, 22.51%, 17.09% in Han, 42.19%, 27.78%, 16.20% in Uygur, 37.02%, 21.11%, 17.77% in Kazak. "

Related Drugs and Biologics

1.	Cholesterol
2.	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)
3.	atorvastatin (Lipitor)
4.	LDL Cholesterol
5.	Lovastatin (Mevacor)
6.	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
7.	Triglycerides (Triacylglycerol)
8.	Pravastatin (Pravachol)
9.	Simvastatin (Zocor)
10.	Coenzyme A (CoA)

Related Therapies and Procedures

1.	Stents
2.	Oral Administration
3.	Renal Dialysis (Hemodialysis)
4.	Transplants (Transplant)
5.	Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)